Press & News

The next generation biopharmaceuticals

Press releases 2019

2019-05-17

Interim Report – January to March 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter of 2019.[read more]

Older press releases

2019-03-28

Interview with Affibody’s CEO (in Swedish)

2019-03-20

Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

Solna, Sweden & Boston, USA, March 20, 2019. Affibody AB and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases.[read more]

2019-02-22

Affibody Announces Fully Guaranteed Rights Issue

Solna, Sweden, February 22, 2019. Affibody Medical AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the decision to carry out a capitalization of approximately SEK 150 million through a fully guaranteed...[read more]

Affibodys latest Press releases

2019-05-17

Interim Report – January to March 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q1 (May 17, 2019)

Investor information